Clinical Characteristics and Risk Factors for Mortality in Patients with Meningitis Caused by Staphylococcus aureus and Vancomycin Minimal Inhibitory Concentrations Against These Isolates

Journal of Microbiology, Immunology and Infection

Volumn 43, Issue 6, 2010, Pages 470-477

  Huang, Wen Chi ^a   Lee, Chen Hsiang ^a   Liu, Jien Wei ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Bacterial meningitis; Infective endocarditis; Minimal inhibitory concentration; Staphylococcus aureus; Vancomycin

Indexed keywords

ANTIBIOTIC AGENT; VANCOMYCIN;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL ENDOCARDITIS; BACTERIAL MENINGITIS; BACTERIUM ISOLATE; CHILD; CLINICAL FEATURE; CONTROLLED STUDY; EPSILOMETER TEST; FEMALE; HOSPITAL PATIENT; HUMAN; INFANT; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; NEUROSURGERY; NEWBORN; NONHUMAN; PRESCHOOL CHILD; RETROSPECTIVE STUDY; RISK FACTOR; SCHOOL CHILD; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; FEVER; HOSPITAL MORTALITY; HUMANS; INFANT; INFANT, NEWBORN; MALE; MENINGITIS, BACTERIAL; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; RISK FACTORS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TAIWAN; VANCOMYCIN; YOUNG ADULT;

EID: 78650742545     PISSN: 16841182     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1684-1182(10)60073-4     Document Type: Article

References (37)

1. Chang WN, Lu CH, Wu JJ, Chang HW, Tsai YC, Chien FT, et al. Staphylococcus aureus meningitis in adults: a clinical comparison of infections caused by methicillin-resistant and methicillin-sensitive strain. Infection 2001, 29:245-250.
2. Durand ML, Calderwood SB, Weber DJ, Miller SI, Southwick FS, Caviness VS, et al. Acute bacterial meningitis in adults-A review of 493 episodes. The New England Journal of Medicine 1993, 328:21-28.
3. Pintado V, Fortún J, Cobo J, Navas E, Quereda C, Corral I, et al. Clinical study of 44 cases of Staphylococcus aureus meningitis. Eur J Clin Microbiol Infect Dis 2002, 21:864-868.
4. Lode HM Clinical Impact of antibiotics-resistant Gram-positive pathogens. Clin Microbiol Infect 2009, 15:212-217.
5. Lu C, Chang W Adults with meningitis caused by oxacillin-resistant Staphylococcus aureus. Clin Infect Dis 2000, 31:723-727.
6. Levine DP Vancomycin: a history. Clin Infect Dis 2006, 42:S5-12.
7. Stevens DL The role of vancomycin in the treatment paradigm. Clin Infect Dis 2006, 42:S51-S57.
8. Moise-Broder PA, Sakoulas G, Eliopoulos GM, Schentag JJ, Forrest A, Moellering RC Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin Infect Dis 2004, 38:1700-1705.
9. Lodise TP, Graves J, Evans A, Graffunder E, Helmecke M, Lomaestro BM, et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrobial Agents Chemother 2008, 52:3315-3320.
10. NCCLS Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically 2000, NCCLS, Wayne PA, Approved standard: M7-A5. 5th edition.
11. Brown Derek FJ, Edwards DI, Hawkey PM, Morrison D, Ridgway GL, Towner KJ Guidelines for the laboratory diagnosis and susceptibility testing of methicillin-resistant Staphylococcus aureus (MRSA). J Antimicrobial Chemother 2005, 56:1000-1018.
12. Clinical and Laboratory Standards Institute Performance Standards for Antimicrobial Susceptibility Testing: 18th Informational Supplement M100-S18 2008, Clinical and Laboratory Standards Institute, Wayne.
13. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM CDC definitions for nosocomial infections. Am J Infect Control 1988, 16:128-140.
14. Durack DT, Lukes AS, Bright DK New criteria for diagnosis of infective endocarditis; utilization of specific echocardiographic findings. Duke Endocarditis Service. Am J Med 1994, 96:200-209.
15. Johnson LB, Almoujahed MO, Ilg K, Maolood L, Khatib R Staphylococcus aureus bacteremia: compliance with standard treatment, long-term outcome and predictors of relapse. Scand J Infect Dis 2003, 35:782-789.
16. Khatib R, Saeed S, Sharma M, Riederer K, Fakih MG, Johnson LB Impact of initial antibiotics choice and delayed appropriate treatment on the outcome of Staphylococcus aureus bacteremia. Eur J Clin Microbiol Infect Dis 2006, 25:181-185.
17. Schlesinger LS, Ross SC, Schaberg DR Staphylococcus aureus meningitis: a broad-based epidemiologic study. Medicine (Baltimore) 1987, 66:148-156.
18. Jensen AG, Espersen F, Skinhoj P, Rosdahl VT, Frimodt-Moller N Staphylococcus aureus meningitis. A review of 104 nationwide, consecutive cases. Arch Intern Med 1993, 153:1902-1908.
19. Kim JH, Van der Horst C, Mulrow CD, Corey GR Staphylococcus aureus meningitis: review of 28 cases. Rev Infect Dis 1989, 11:698-706.
20. Falco V, Almirante B, Pahissa A, Gasser I, Fernandez-Perez F, Martinez-Vazquez JM Meningitis caused by Staphylococcus aureus. Analysis of 16 cases. Med Clin (Bare) 1990, 94:208-211.
21. Fong IW, Ranalli P Staphylococcus aureus meningitis. QJM 1984, 53:289-299.
22. Gordon JJ, Harter DH, Phair JP Meningitis due to Staphylococcus aureus. Am J Med 1985, 78:965-970.
23. Pedersen M, Benfield TL, Skinhoej P, Jensen AG Haematogenous Staphylococcus aureus meningitis. A 10-year nationwide study of 96 consecutive cases. BMC Infect Dis 2006, 6:49.
24. Roder BL, Wandall DA, Espersen F, Frimodt-Moller N, Skinhoj P, Rosdahl VT Neurologic manifestations in Staphylococcus aureus endocarditis: a review of 260 bacteremic cases in nondrug addicts. Am J Med 1997, 379-386.
25. Chang FY, MacDonald BB, Peacock JE, Musher DM, Triplett P, Mylotte JM, et al. A prospective multicenter study of Staphylococcus aureus bacteremia: incidence of endocarditis, risk factors for mortality, and clinical impact of methicillin resistance. Medicine (Baltimore) 2003, 82:322-332.
26. Tunkel AR, Harrman BH, Laplan SL, Kaufman BA, Roos KL, Scheld WM, et al. IDSA guidelines. Practice guidelines for management of bacterial meningitis. Clin Infect Dis 2004, 39:1267-1284.
27. Rybak MJ, Lomaestro BM, Rotschafer JC, Moellering RC, Craig WA, Billeter M, et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Disease Society of America, and the Society of Health-System Pharmacists, and the Society of Infectious Disease Pharmacists. Clin Infect Dis 2009, 49:325-327.
28. Jourdan C, Convert J, Peloux A, Boussaid O, Grando J, Tigaud S, et al. Adequate intrathecal diffusion of teicoplanin after failure of vancomycin, administered in continuous infusion in three cases of shunt associated meningitis. Pathol Biol (Paris) 1996, 44:389-392.
29. Pfausler B, Spiss H, Beer R, Kamol A, Engelhardt K, Schober M Treatment of staphylococcal ventriculitis associated with external cerebrospinal fluid drains: a prospective randomized trial of intravenous compared with intraventricular vancomycin therapy. J Neurosurg 2003, 98:1040-1044.
30. Bennett MI, Tai YM, Symonds JM Staphylococcal meningitis following synchromed intrathecal pump implant: a case report. Pain 1994, 56:243-244.
31. Pfausler B, Haring HP, Kampfl A, Wissel J, Schober M, Schmutzhard E Cerebrospinal fluid (CSF) pharmacokinetics of intraventricular vancomycin in patients with staphylococcal ventriculitis associated with external CSF drainage. Clin Infect Dis 1997, 25:733-735.
32. Matsubara H, Makimoto A, Higa T, Kawamoto H, Kanda Y, Kami M, et al. Successful treatment of meningoencephalitis caused by methicillin-resistant Staphylococcus aureus with intrathecal vancomycin in a allogenic peripheral blood stem cell transplant recipient. Bone Marrow Transplant 2003, 31:65-67.
33. Luer MS, Hatton J Vancomycin administration into the cerebro-spinal fluid: a review. Ann Pharmacother 1993, 27:912-921.
34. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC, Eliopoulos FM Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004, 42:2398-2402.
35. Soriano A, Marco F, Martinez JA, Pisos E, Almela M, Dimova VP, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008, 46:193-200.
36. Steinkraus G, White R, Friedrich L Vancomycin MIC creep in non-vancomycin -intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. J Antimicrobial Chemother 2007, 60:788-794.
37. Clinical and Laboratory Standards Institute Performance Standards for Antimicrobial Susceptibility Testing: 16th Informational Supplement M100-S16 2006, Clinical and Laboratory Standards Institute, Wayne.